Orphazyme Revenue vs. Cash Per Share
| ORPHA Stock | DKK 950.00 39.80 4.02% |
For Orphazyme profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Orphazyme to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Orphazyme AS utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Orphazyme's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Orphazyme AS over time as well as its relative position and ranking within its peers.
Orphazyme |
Orphazyme AS Cash Per Share vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Orphazyme's current stock value. Our valuation model uses many indicators to compare Orphazyme value to that of its competitors to determine the firm's financial worth. Orphazyme AS is rated top company in revenue category among its peers. It also is considered to be number one stock in cash per share category among its peers . The ratio of Revenue to Cash Per Share for Orphazyme AS is about 1,740,048 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Orphazyme by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Orphazyme's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Orphazyme Revenue vs. Competition
Orphazyme AS is rated top company in revenue category among its peers. Market size based on revenue of Health Care industry is now estimated at about 15.18 Billion. Orphazyme adds roughly 36.19 Million in revenue claiming only tiny portion of equities under Health Care industry.
Orphazyme Cash Per Share vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Orphazyme |
| = | 36.19 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Orphazyme |
| = | 20.80 X |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Orphazyme Cash Per Share Comparison
Orphazyme is currently under evaluation in cash per share category among its peers.
Orphazyme Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Orphazyme, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Orphazyme will eventually generate negative long term returns. The profitability progress is the general direction of Orphazyme's change in net profit over the period of time. It can combine multiple indicators of Orphazyme, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Orphazyme AS, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark. Orphazyme is traded on Copenhagen Stock Exchange in Denmark.
Orphazyme Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Orphazyme. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Orphazyme position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Orphazyme's important profitability drivers and their relationship over time.
Use Orphazyme in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Orphazyme position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Orphazyme will appreciate offsetting losses from the drop in the long position's value.Orphazyme Pair Trading
Orphazyme AS Pair Trading Analysis
The ability to find closely correlated positions to Orphazyme could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Orphazyme when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Orphazyme - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Orphazyme AS to buy it.
The correlation of Orphazyme is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Orphazyme moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Orphazyme AS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Orphazyme can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Orphazyme position
In addition to having Orphazyme in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Aggressive Funds Thematic Idea Now
Aggressive Funds
Funds or Etfs that attempt to achieve high capital gains by investing in companies with high growth potential and above average risk. The Aggressive Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Aggressive Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Orphazyme Stock
To fully project Orphazyme's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Orphazyme AS at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Orphazyme's income statement, its balance sheet, and the statement of cash flows.